Filipino Filipino
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Pinakabagong Balita

Unang Gene Therapy para sa Mga Matanda na may Malalang Hemophilia A, ang ROCTAVIAN™ ng BioMarin na Inaprubahan ng European Commission (EC)

 

Nakatanggap ang BioMarin ng Positibong CHMP Opinion sa Europe para sa Valoctocogene Roxaparvovec Gene Therapy para Gamutin ang Matanda na may Malalang Hemophilia A

 

Positibong Initial Clinical Data mula sa B-LIEVE Dose-Confirmation Trial para sa FLT180a sa Hemophilia B Itinanghal sa International Society on Thrombosis and Haemostasis Congress

 

Sinimulan ng Freeline ang Dosing ng Second Cohort sa B-LIEVE Dose Confirmation Trial ng FLT180a sa Hemophilia B

 

Back To Top
Imahen

Please enable the javascript to submit this form

tungkol sa

Sinusuportahan ng mga grant na pang-edukasyon mula sa Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, at uniQure, Inc.

Mahalagang SSL